Genocea Biosciences, Inc. (GNCAQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Jan 21, 2025, 9:30 AM EST
Genocea Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | 2016 - 2012 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | 2016 - 2012 |
| Net Income | -37.19 | -33.2 | -43.71 | -38.95 | -27.81 | -56.71 | Upgrade
|
| Depreciation & Amortization | 0.88 | 0.86 | 0.54 | 0.7 | 0.69 | 1.23 | Upgrade
|
| Other Amortization | 0.7 | 0.7 | 0.6 | 0.4 | 0.76 | 0.29 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | -0.08 | -0.02 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 1.03 | Upgrade
|
| Stock-Based Compensation | 3.96 | 3.64 | 1.97 | 1.84 | 2.15 | 4.23 | Upgrade
|
| Other Operating Activities | -18.81 | -19.53 | -4.09 | -0.4 | -12 | 0.5 | Upgrade
|
| Change in Accounts Payable | -0.06 | -0.06 | 0.03 | -1.11 | -2.1 | 0.49 | Upgrade
|
| Change in Unearned Revenue | 0.06 | 0.06 | 1.64 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 2.28 | 2.16 | 1.37 | -0.21 | -2.84 | 1.36 | Upgrade
|
| Operating Cash Flow | -48.19 | -45.37 | -41.65 | -37.73 | -41.24 | -47.6 | Upgrade
|
| Capital Expenditures | -3.14 | -3.29 | -2.59 | -1.14 | -0.24 | -1.18 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.04 | 0.08 | 0.03 | 0.05 | 0.11 | 0.15 | Upgrade
|
| Investment in Securities | - | - | - | - | - | 35.94 | Upgrade
|
| Investing Cash Flow | -3.1 | -3.21 | -2.56 | -1.09 | -0.13 | 34.91 | Upgrade
|
| Long-Term Debt Issued | - | 10 | - | - | 0.59 | - | Upgrade
|
| Long-Term Debt Repaid | - | -15.23 | -0.13 | -1.92 | -0.54 | -3.15 | Upgrade
|
| Net Debt Issued (Repaid) | -2.5 | -5.23 | -0.13 | -1.92 | 0.06 | -3.15 | Upgrade
|
| Issuance of Common Stock | 7.89 | 11.57 | 83.98 | 54.82 | 55.53 | 0.89 | Upgrade
|
| Other Financing Activities | - | -0.38 | - | - | -0.13 | -0.2 | Upgrade
|
| Financing Cash Flow | 5.39 | 5.96 | 83.85 | 52.9 | 55.46 | -2.46 | Upgrade
|
| Net Cash Flow | -45.9 | -42.62 | 39.64 | 14.08 | 14.09 | -15.15 | Upgrade
|
| Free Cash Flow | -51.33 | -48.66 | -44.24 | -38.87 | -41.48 | -48.78 | Upgrade
|
| Free Cash Flow Margin | -2685.82% | -2965.14% | -3255.04% | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.74 | -0.71 | -0.95 | -1.88 | -4.02 | -13.64 | Upgrade
|
| Cash Interest Paid | 0.55 | 0.58 | 1.05 | 1.1 | 1.07 | 1.19 | Upgrade
|
| Levered Free Cash Flow | -31.45 | -32.08 | -26.42 | -24.64 | -25.94 | -27.37 | Upgrade
|
| Unlevered Free Cash Flow | -30.78 | -31.38 | -25.49 | -23.64 | -25.23 | -26.31 | Upgrade
|
| Change in Net Working Capital | -2.16 | 0.04 | -3.35 | 1.07 | 3.53 | -2.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.